Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 1, 2014, Pages 107-110

  Galvão, Violeta Régnier ^a   Aun, Marcelo Vivolo ^a   Kalil, Jorge ^a   Castells, Mariana ^b   Giavina Bianchi, Pedro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; PHENYTOIN; PREDNISOLONE; PREDNISONE; VIRUS DNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE REPORT; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRESS SYNDROME; DRUG DOSE REDUCTION; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EPSTEIN BARR VIRUS; ESOPHAGUS BIOPSY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOSIS; MACULOPAPULAR RASH; MIDDLE AGED; MOUTH LESION; POLYMERASE CHAIN REACTION; PROPHYLAXIS; PURPURIC RASH; SEIZURE; SKIN BIOPSY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS REACTIVATION;

ADRENAL CORTEX HORMONES; ANTICONVULSANTS; BIOPSY; DRUG HYPERSENSITIVITY SYNDROME; DRUG RESISTANCE; EPSTEIN-BARR VIRUS INFECTIONS; ESOPHAGOSCOPY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PHENYTOIN; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84891636213     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.11.008     Document Type: Article

References (9)

1. Camous X., Calbo S., Picard D., Musette P. Drug reaction with eosinophilia and systemic symptoms: an update on pathogenesis. Curr Opin Immunol 2012, 24:730-735.
2. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., Halevy S., Davidovici B.B., Mockenhaupt M., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really existα. Br J Dermatol 2007, 156:609-611.
3. Shiohara T., Inaoka M., Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006, 55:1-8.
4. Kano Y., Inaoka M., Sakuma K., Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. Toxicology 2005, 209:165-167.
5. Yazicioglu M., Elmas R., Turgut B., Genchallac T. The association between DRESS and the diminished numbers of peripheral B lymphocytes and natural killer cells. Pediatr Allergy Immunol 2012, 23:289-296.
6. Pritchett J.C., Nanau R.M., Neuman M.G. The link between hypersensitivity syndrome reaction development and human herpes virus-6 reactivation. Int J Hepatol 2012, 2012:1-19.
7. Santhamoorthy P., Alexander K.J., Alshubaili A. Intravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenytoin. Ann Indian Acad Neurol 2012, 15:320-322.
8. Joly P., Janela B., Tetart F., Rogez S., Picard D., DIncan M., et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol 2012, 148:543-544.
9. Kito Y., Ito T., Tokura Y., Hashizume H. High-dose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome. Acta Derm Venerol 2012, 92:100-101.